Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence…mehr
Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
1. Defining treatment-resistant depression, difficult-to-treat depression, and staging treatment intensity 2. Clinical and epidemiological predictors of treatment-resistant depression 3. The economic burden of treatment-resistant depression: Cost-of-illness perspective 4. The neurobiology of treatmentresistant depression 5. Modeling treatment-resistant depression in the preclinical setting 6. Treatment algorithms for treatment-resistant depression 7. Tools to aid precision treatments to prevent or manage treatmentresistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence 8. Tricyclic antidepressants for treatment-resistant depression 9. Monoamine oxidase inhibitors for treatment-resistant depression 10. Switching antidepressants in patients with treatment-resistant depression 11. Adjunctive strategies for treatment-resistant depression 12. Combining antidepressants to address treatment-resistant depression 13. Ketamine/esketamine for treatment-resistant depression 14. Psychedelic agents for treatmentresistant depression 15. Inflammation and treatment resistance: Mechanisms and treatment implications 16. Opioid agents for treatmentresistant depression 17. Transcranial magnetic stimulation for treatment-resistant depression 18. tDCS for treatment-resistant depression 19. ECT for treatment-resistant depression 20. MST for treatment-resistant depression 21. VNS for treatment-resistant depression 22. Deep brain stimulation for treatment-resistant depression 23. Other neurosurgical interventions for treatment-resistant depression 24. Treatment-resistant psychotic depression 25. Evidence-based psychotherapy for treatment-resistant depression 26. Treatment-resistant bipolar depression 27. Treatment-resistant depression in child and adolescents 28. Treatment-resistant depression in geriatrics 29. Identification and management of anxious depression in patients with treatment-resistant depression 30. Managing treatment-resistant depression with comorbid personality disorders 31. Managing treatment-resistant depression with comorbid substance use disorders 32. Managing treatment-resistant depression in the setting of chronic pain 33. Inhaled gases for treatmentresistant major depression 34. Drugs under investigation for treatment-resistant depression 35. Chronotherapeutics for treatmentresistant depression 36. Managing treatment resistant depression in primary care settings 37. Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause 38. Lifestyle interventions for treatment-resistant depression 39. Managing the risk of suicide in people with treatment-resistant depression 40. Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatmentresistant depression
1. Defining treatment-resistant depression, difficult-to-treat depression, and staging treatment intensity 2. Clinical and epidemiological predictors of treatment-resistant depression 3. The economic burden of treatment-resistant depression: Cost-of-illness perspective 4. The neurobiology of treatmentresistant depression 5. Modeling treatment-resistant depression in the preclinical setting 6. Treatment algorithms for treatment-resistant depression 7. Tools to aid precision treatments to prevent or manage treatmentresistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence 8. Tricyclic antidepressants for treatment-resistant depression 9. Monoamine oxidase inhibitors for treatment-resistant depression 10. Switching antidepressants in patients with treatment-resistant depression 11. Adjunctive strategies for treatment-resistant depression 12. Combining antidepressants to address treatment-resistant depression 13. Ketamine/esketamine for treatment-resistant depression 14. Psychedelic agents for treatmentresistant depression 15. Inflammation and treatment resistance: Mechanisms and treatment implications 16. Opioid agents for treatmentresistant depression 17. Transcranial magnetic stimulation for treatment-resistant depression 18. tDCS for treatment-resistant depression 19. ECT for treatment-resistant depression 20. MST for treatment-resistant depression 21. VNS for treatment-resistant depression 22. Deep brain stimulation for treatment-resistant depression 23. Other neurosurgical interventions for treatment-resistant depression 24. Treatment-resistant psychotic depression 25. Evidence-based psychotherapy for treatment-resistant depression 26. Treatment-resistant bipolar depression 27. Treatment-resistant depression in child and adolescents 28. Treatment-resistant depression in geriatrics 29. Identification and management of anxious depression in patients with treatment-resistant depression 30. Managing treatment-resistant depression with comorbid personality disorders 31. Managing treatment-resistant depression with comorbid substance use disorders 32. Managing treatment-resistant depression in the setting of chronic pain 33. Inhaled gases for treatmentresistant major depression 34. Drugs under investigation for treatment-resistant depression 35. Chronotherapeutics for treatmentresistant depression 36. Managing treatment resistant depression in primary care settings 37. Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause 38. Lifestyle interventions for treatment-resistant depression 39. Managing the risk of suicide in people with treatment-resistant depression 40. Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatmentresistant depression
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
